Effect of low and moderate doses of recombinant human erythropoietin on the haematological response in premature infants on a high protein and iron intake.
There is no consensus regarding protein intake and the doses of recombinant human erythropoietin (r-HuEpo) and iron in the treatment of anaemia of prematurity (AOP). This open, randomized study has compared the effectiveness of 50 IU r-HuEpo/kg with that of 100 IU/kg, both given subcutaneously thrice weekly. In addition, two different protein supplements have been compared; lyophilized human milk protein and a commercial cow's milk product. Total protein intake was 3 g/kg per day. Daily iron dose was 18-36 mg. "Healthy" preterm infants (n = 32, birth weight: 800-1400 g, gestational age < or = 31 weeks) were studied from age 3 to 8 weeks. The two protein regimens yielded no differences in body growth, reticulocyte count or Hb concentration. In both r-HuEpo dose groups increased number of reticulocytes followed start of treatment; higher levels were, however, found in the group receiving 100 IU/kg. Mean Hb concentration plateaued at 12 g/dl for infants receiving 100 IU/kg, at 11 g/dl in the 50 IU/kg group. Even though serum levels of ferritin and transferrin saturation indicated no iron deficiency, soluble transferrin receptor increased in both groups, more rapidly and to higher levels in the 100 IU/kg group. In addition, the number of infants having more than 8% hypochromic red cells increased in both groups.


CONCLUSIONS
Commercial cow's milk protein added to human milk was as good as human milk protein supplementation in supporting growth and erythropoiesis. Fifty IU/kg r-HuEpo thrice weekly during AOP stimulated erythropoiesis significantly, but less so than 100 IU/kg. Even when using high oral doses of iron to preterms receiving r-HuEpo, our data suggested a certain degree of iron deficient erythropoiesis.
Bechensteen
A G
AG
Department of Paediatrics, Ullevå I University Hospital, Oslo, Norway.
Hågå
P
P
Halvorsen
S
S
Liestøl
K
K
Lindemann
R
R
Whitelaw
A
A
Tølløfsrud
P A
PA
Daae
L
L
Thorstensen
K
K
Sundal
E
E
D000751:Anemia, Neonatal / Q000517:prevention & control / Q000628:therapy*; D000818:Animals; D003131:Combined Modality Therapy; D004044:Dietary Proteins / Q000008:administration & dosage*; D004920:Erythropoiesis / Q000502:physiology; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006128:Growth / Q000502:physiology; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007227:Infant Nutritional Physiological Phenomena; D007231:Infant, Newborn; D007234:Infant, Premature; D007501:Iron / Q000097:blood / Q000627:therapeutic use*; D016014:Linear Models; D016015:Logistic Models; D008297:Male; D008892:Milk; D008895:Milk, Human; D011990:Receptors, Transferrin / Q000097:blood; D011994:Recombinant Proteins; D017701:Reticulocyte Count
D004044:Dietary Proteins; D006454:Hemoglobins; D011990:Receptors, Transferrin; D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron